Skip to main content

Mogamulizumab Pregnancy and Breastfeeding Warnings

Medically reviewed by Last updated on Nov 7, 2022.

Mogamulizumab is also known as: Poteligeo

Mogamulizumab Pregnancy Warnings

Animal studies did not show a potential for adverse developmental outcomes at maternal systemic exposures 27 times the exposure in patients at the recommended dose. There are no controlled data in human pregnancy. It is not known whether this drug can cause fetal harm or adversely affect reproductive capacity in humans.

AU TGA pregnancy category C: Drugs which, owing to their pharmacological effects, have caused or may be suspected of causing, harmful effects on the human fetus or neonate without causing malformations. These effects may be reversible. Accompanying texts should be consulted for further details.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D and X are being phased out.

Use is not recommended.

AU TGA pregnancy category: C
US FDA pregnancy category: Not assigned.

Risk Summary: Animal studies from the start of organogenesis through delivery did not show a potential for adverse developmental outcomes at maternal systemic exposures 27 times the exposure in human patients at the recommended dose. IgG is known to cross the placental barrier and was detected in fetal plasma in animal studies; therefore, this drug has the potential to be transmitted from the mother to the developing fetus.

-Adequate methods of contraception should be encouraged.
-Verify negative pregnancy status in females of reproductive potential prior to initiating therapy.
-If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus.
-Advise females of reproductive potential to use effective contraception during therapy and for 3 months after.

See references

Mogamulizumab Breastfeeding Warnings

Safety has not been established.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

-The effects in the nursing infant are unknown.
-Human IgGs are known to be excreted in breast milk during the first few days after birth, which decreases to low concentrations soon afterwards; therefore, a risk to the breast-fed child cannot be excluded during this short period.

See references

References for pregnancy information

  1. "Product Information. Poteligeo (mogamulizumab)." Kyowa Kirin, Inc (2018):

References for breastfeeding information

  1. "Product Information. Poteligeo (mogamulizumab)." Kyowa Kirin, Inc (2018):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.